These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 34813050)

  • 1. Atogepant: First Approval.
    Deeks ED
    Drugs; 2022 Jan; 82(1):65-70. PubMed ID: 34813050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atogepant for the Preventive Treatment of Migraine.
    Ailani J; Lipton RB; Goadsby PJ; Guo H; Miceli R; Severt L; Finnegan M; Trugman JM;
    N Engl J Med; 2021 Aug; 385(8):695-706. PubMed ID: 34407343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atogepant (Qulipta) for migraine prevention.
    Med Lett Drugs Ther; 2021 Nov; 63(1636):169-171. PubMed ID: 35085204
    [No Abstract]   [Full Text] [Related]  

  • 4. A Single Supratherapeutic Dose of Atogepant Does Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized, Single-Dose, Phase 1 Crossover Trial.
    Boinpally R; McNamee B; Yao L; Butler M; McGeeney D; Borbridge L; Periclou A
    Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1099-1107. PubMed ID: 33942560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atogepant: an emerging treatment for migraine.
    Rustichelli C; Avallone R; Ferrari A
    Expert Opin Pharmacother; 2022 Apr; 23(6):653-662. PubMed ID: 35319319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults.
    Min KC; Kraft WK; Bondiskey P; Colón-González F; Liu W; Xu J; Panebianco D; Mixson L; Dockendorf MF; Matthews CZ; Boinpally R
    Clin Transl Sci; 2021 Mar; 14(2):599-605. PubMed ID: 33142014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trial.
    Lipton RB; Halker Singh RB; Mechtler L; McVige J; Ma J; Yu SY; Stokes J; Dabruzzo B; Gandhi P; Ashina M
    Cephalalgia; 2023 Aug; 51(8):3331024231190296. PubMed ID: 37638400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ubrogepant: First Approval.
    Scott LJ
    Drugs; 2020 Feb; 80(3):323-328. PubMed ID: 32020557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
    Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
    Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial.
    Lipton RB; Nahas SJ; Pozo-Rosich P; Bilchik T; McAllister P; Finnegan M; Liu Y; Chalermpalanupap N; Dabruzzo B; Dodick DW
    J Headache Pain; 2024 May; 25(1):83. PubMed ID: 38773375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecule CGRP receptor antagonists for the preventive treatment of migraine: A review.
    Dos Santos JBR; da Silva MRR
    Eur J Pharmacol; 2022 May; 922():174902. PubMed ID: 35358493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atogepant for migraine.
    Bedrin K; Ailani J
    Drugs Today (Barc); 2022 Aug; 58(8):399-405. PubMed ID: 35983926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial.
    Tassorelli C; Nagy K; Pozo-Rosich P; Lanteri-Minet M; Sacco S; Nežádal T; Guo H; De Abreu Ferreira R; Forero G; Trugman JM
    Lancet Neurol; 2024 Apr; 23(4):382-392. PubMed ID: 38364831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atogepant for Migraine Prevention: A Systematic Review of Efficacy and Safety.
    Singh A; Balasundaram MK
    Clin Drug Investig; 2022 Apr; 42(4):301-308. PubMed ID: 35230651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atogepant: Mechanism of action, clinical and translational science.
    Boinpally R; Shebley M; Trugman JM
    Clin Transl Sci; 2024 Jan; 17(1):e13707. PubMed ID: 38266063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-Dose Pharmacokinetics and Safety of Atogepant in Adults With Hepatic Impairment: Results From an Open-Label, Phase 1 Trial.
    Boinpally R; Jakate A; Butler M; Borbridge L; Periclou A
    Clin Pharmacol Drug Dev; 2021 Jul; 10(7):726-733. PubMed ID: 33501783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The preclinical discovery and development of atogepant for migraine prophylaxis.
    Baraldi C; Beier D; Martelletti P; Pellesi L
    Expert Opin Drug Discov; 2024 Jul; 19(7):783-788. PubMed ID: 38856039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rimegepant (Nurtec ODT) for acute treatment of migraine.
    Med Lett Drugs Ther; 2020 May; 62(1597):70-72. PubMed ID: 32555113
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacologic characterization of atogepant: A potent and selective calcitonin gene-related peptide receptor antagonist.
    Moore E; Bell IM; Fraley ME; Burgey CS; White RB; Li CC; Regan CP; Danziger A; McGaraughty SP; Naseri Kouzehgarani G; Salvatore C; Banerjee P
    Cephalalgia; 2024 Jan; 44(1):3331024231226186. PubMed ID: 38215228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials.
    Rizzoli P; Marmura MJ; Robblee J; McVige J; Sacco S; Nahas SJ; Ailani J; De Abreu Ferreira R; Ma J; Smith JH; Dabruzzo B; Ashina M
    J Headache Pain; 2024 Mar; 25(1):35. PubMed ID: 38462625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.